Insomnia and Sleep-Onset Delay: Why Bedtime Anxiety Keeps People Awake and How to Break the Cycle

Insomnia is a clinical condition characterized by persistent difficulty initiating sleep, maintaining sleep, or achieving restorative sleep, occurring despite adequate opportunity and resulting in daytime impairment. Sleep-onset delay—commonly experienced as “can’t fall asleep” after going to bed—is the hallmark of many insomnia presentations and may be accompanied by hyperarousal, worry, and conditioned wakefulness. In health terms, insomnia is not merely short sleep; it involves a maladaptive arousal–sleep interaction in which the nervous system remains in a heightened state at the time the body should transition into sleep.

At the neurobiological level, insomnia is strongly associated with dysregulated arousal systems. The orexin (hypocretin) network, which promotes wakefulness, can be overactive relative to sleep drive, particularly when stress or cues repeatedly signal threat or performance demands. Insomnia also involves altered balance in GABAergic and glutamatergic signaling that affects cortical excitability. Functional studies frequently implicate prefrontal–limbic circuits involved in threat processing, cognitive control, and emotional regulation. As a result, sleep becomes harder to start because the brain treats bedtime as a time to evaluate, monitor, or worry rather than to downshift.

Cognitive processes play a central role. When a person goes to bed and time passes without sleep, they often develop performance anxiety (e.g., “I must sleep now”), which increases sympathetic activation and attention to internal sensations. This is reinforced by selective monitoring of sleep-related thoughts and bodily cues (heart rate, fatigue level, time remaining). Over time, a pattern of conditioned arousal can develop: the bed and bedroom become associated with wakefulness because the individual repeatedly attempts to sleep while feeling tense and alert. The “sleep pressure” that should accrue across the day is effectively counteracted by mental arousal and maladaptive beliefs.

Insomnia can be primary (present without another disorder) or secondary to psychiatric, medical, or environmental conditions. Common comorbidities include generalized anxiety disorder, depression, post-traumatic stress disorder, restless legs syndrome, chronic pain, and substance-related sleep disturbance (including caffeine and nicotine). Endocrine and medical contributors—such as thyroid disease, gastroesophageal reflux, and obstructive sleep apnea—should be considered when symptoms include snoring, witnessed apneas, nocturnal choking, or persistent fatigue.

A practical clinical framing is the 3P model: predisposing factors (genetic vulnerability, temperament, childhood stress), precipitating factors (life events, new routines, health issues), and perpetuating factors (maladaptive behaviors, cognitive arousal, irregular schedules). The perpetuating factors are often the most actionable. For example, spending prolonged periods awake in bed, using the bed for non-sleep activities, or napping late in the day can weaken the homeostatic drive for sleep and strengthen wake conditioning.

Diagnosis relies on clinical history, symptom duration (often at least 3 nights per week for 3 months for chronic insomnia), and assessment of daytime consequences such as fatigue, irritability, impaired concentration, and mood changes. Sleep diaries and questionnaires like the Insomnia Severity Index can help quantify severity and track patterns. Actigraphy or polysomnography may be indicated when circadian rhythm disorders, sleep apnea, or other sleep disorders are suspected.

First-line treatment is cognitive behavioral therapy for insomnia (CBT-I), an evidence-based, structured intervention that targets both behaviors and cognition. Stimulus control instructions reduce time awake in bed (e.g., leave the bedroom when unable to sleep and return only when sleepy). Sleep restriction therapy can consolidate sleep by temporarily limiting time in bed to increase sleep efficiency, then gradually expanding it as sleep improves. Cognitive therapy addresses maladaptive beliefs about sleep and reduces bedtime performance pressure. Relaxation and mindfulness-based strategies can lower physiological arousal.

Pharmacotherapy is sometimes used for short-term relief, but it is generally not a stand-alone solution because it may not address perpetuating cognitive and behavioral factors. Medication choices depend on patient factors and risk profiles; risks can include next-day impairment, falls, tolerance, dependence, and complex sleep behaviors with some classes. Melatonin or melatonin receptor agonists may be considered when circadian timing is a major component (e.g., delayed sleep-wake phase), rather than classic sleep-onset anxiety.

Prevention and self-management focus on stabilizing the sleep schedule, limiting caffeine and alcohol near bedtime, reducing evening light exposure, and creating a consistent wind-down routine. When bedtime thoughts become intrusive, shifting attention away from sleep outcome and toward non-striving relaxation may reduce arousal. Seeking evaluation is appropriate when insomnia persists, causes significant daytime impairment, or co-occurs with symptoms suggesting medical or psychiatric etiologies.

Finally, insomnia is treatable. With appropriate assessment and CBT-I–based interventions, many patients experience meaningful improvements in sleep initiation and overall quality of life by interrupting the arousal–worry loop and re-establishing conditioned sleep cues. Source: [@AzatothT666]